1. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Рас­пространенность артериальной гипертонии в России: информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3–7.
2. Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В. и др. Перспективы лечения артериальной гипертонии. Артериальная гипертензия. 2013; 19 (1): 280–9.
3. Оганов Р.Г., Шальнова С.А., Деев А.Д. и др. Артериальная гипертония, смертность от сердечно-сосудистых заболеваний и вклад в продолжительность жизни населения. Профилактика заболеваний и укрепление здоровья. 2001; 3: 3–7.
4. Шальнова С.А., Деев А.Д., Вихирева О.В. Артериальная гипертония глазами амбулаторных пациентов. Первые результаты исследования ГАРАНТ. Кардиоваскулярная терапия и профилактика. 2007; 6 (5).
5. Krousel-Wood M, Thomas S, Munter P et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19 (4): 357–62.
6. Miller NH, Hill M, Kottke T et al. The multilevel compliance challenge: recommendations for a call to action. Circulation 1997; 95 (4): 1085–900.
7. Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
8. Sokol MC, McGuigan KA, Verbrugge RR et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43 (6): 521–30.
9. Corrao G, Parodi A, Zambon A et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584–90.
10. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
11. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1281–357.
12. James P, Oparil S, Carter B et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
13. Go A, Bauman M, Coleman King S et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol 2014; 63 (12): 1230–8.
14. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5–26.
15. Weber M, Schiffrin E, White W. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014; 16 (1): 14–26.
16. Clinical management of primary hypertension in adults. NICE clinical guideline. 2011.
17. Белоусов Ю.Б., Леонова М.В., Белоусов Д.Ю. и др. Результаты фармакоэпидемиологического исследования больных артериальной гипертонией в России (ПИФАГОР II). Качественная клин. практика. 2004; 1: 17–27.
18. Кобалава Ж.Д., Котовская Ю.В., Лукьянова Е.А. от имени врачей-участников программы КОНСТАНТА. Комбини­рованная терапия артериальной гипертонии фикси­рованной комбинацией периндоприл А/амлодипин в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология. 2013; 53 (6): 25–34.
19. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodi­pine or hydrochlorothiazide for hypertension in high-risk patients. 
N Engl J Med. 2008; 359: 2417–28.
20. Jamerson KA, Devereux R, Bakris GL et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 2011; 57 (2): 174–9.
21. Sever PS, Dahlof B, Poulter NR et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
22. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
23. Wald DS, Law M, Morris JK et al. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290–300.
24. Roca-Cusachs A et al. Grupo Español de Estudio de Enalapril/Nitrendipino. Hipertensión 2002; 19 (Suppl. 2): 175 (abstr 85-T).
25. De la Sierra A et al. J Hum Hypertens 2004; 18: 215–22.
26. Makani H, Bangalore S, Romero J et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011; 124 (2): 128–35.
27. Benetos A, Cambien F, Gautier S et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28 (6): 1081–4.
28. Albaladejo P, Bouaziz H, Duriez M et al. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 1994; 23: 74–82.
29. Kool MJ, Lustermans FA, Breed JG et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13: 839–48.
30. Агеев Ф.Т., Середенина Е.М., Орлова Я.А. и соавт. Оценка влияния ингибитора ангиотензинпревращающего фер­мента моэксиприла на функциональное состояние сосу­дистой стенки у больных с артериальной гипертонией II–III степени. Кардиология. 2007; 8: 49–53.
31. Dima I, Vlachopoulos C, Alexopoulos N et al. Association of Arterial Stiffness With the Angiotensin-Converting Enzyme Gene Polymorphism in Healthy Individuals. Am J Hypertens 2008; 21 (12): 1354–8.
32. Benetos A, Gautier S, Ricard S et al. Influence of angiotensin converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996; 94: 698–703.
33. Kim KH, Jeong MH, Cho SH et al. Clinical Effects of Calcium Channel Blocker and Angiotensin Converting Enzyme Inhibitor on Endothelial Function and Arterial Stiffness in Patients with Angina Pectoris. J Korean Med Sci 2009; 24: 223–31.
34. Wislǿff T, Selmer RM, Halvorsen S et al.Choice of generic antihypertensive drugs for the primary prevention of cardiovascular 
disease – a cost-effectiveness analysis. BMC Cardiovasc Disord 2012; 12: 26.
35. Ong H, Ong L, Ho J. Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiol 2013; 2013: 478597.
36. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical 
trials. Diabetes Metab 2004; 30 (6): 487–96.
37. Costanzo P, Perrone-Filardi P, Petretta M et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 2009; 27 (6): 1136–51.
38. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64.
39. Thijs L, Staessen JA, Beleva S et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306.
40. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
41. Thijs L, Richart T, de Leeuw P et al. Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial. Hypertens 2010; 28 (4):
 865–74.
42. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и соавт. Фармакоэпидемиология артериальной гипертонии в России (по результатам фармакоэпидемиологического исследования ПИФАГОР III). Рос. кардиол. журн. 2011; 2 (88): 9–16.
43. Roca-Cusachs A, Torres F, Horas M et al. Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of 
factorial design. J Cardiovasc Pharmacol 2001; 38 (6): 840–9.
44. De la Sierra A, Roca-Cusachs A, Redὁn J et al. Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study. Clin Drug Investig 2009; 29 (7): 459–69.
45. Eber B et al. Fixkombination Enalapril/Nitrendipin in der täglichen Praxis – Effektivität und Verträglichkeit bei 1.262 österreichischen Hypertonikern. Austrian J Hypertens 2007; 11 (2): 22–5.
46. Trenkwalder P. The Efficacy and Tolerability of an Antihypertensive Fixed Combination of Enalapril and Nitrendipine. Perfusion 2004; 7: 394–9.

Я.А.Орлова

Медицинский научно-образовательный центр ФГОУ ВПО МГУ им. М.В.Ломоносова; кафедра многопрофильной клинической подготовки факультета фундаментальной медицины ФГОУ ВПО МГУ им. М.В.Ломоносова